Ramucirumab drug aliquots can be used for in vitro or in vivo experiments. For biosimilar development, different batches of Ramucirumab drug can be ordered at the same time. Several other reference drugs are also available.
The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.
Find and order your therapeutic molecules through smart filters
Up to 10 batches of original drugs for examining batch-to-batch variations
Up to 80% less compared to the original pharmaceutical price
Shipment within days worldwide according to GDP-standards
Up to 80% less compared to the original pharmaceutical price
| Drug name | Cyramza® |
| INN | Ramucirumab |
| API type | Ramucirumab is a human IgG1 monoclonal antibody produced in murine (NS0) cells by recombinant DNA technology. |
| Pharmacotherapeutic group | Antineoplastic agents, monoclonal antibodies |
| ATC code | L01XC21 |
| Target of antibody | VEGFR2; Synonyms: CD309, FLK1, VEGFR, 6130401C07, Flk-1, Flk1, Krd-1, Ly73, VEGFR-2, sVEGFR2, Vegfr-2, FLK-1, flk-1, vegfr-2, KDR, FLK/KDR, flk1, flk1b, kdrb, si:busm1-205d10.1, si:ch211-254j6.1, si:ch211-278f21.4, wu:fc31a09 |
| General function | |
| Short description | |
| Pharmacodynamic properties (Mechanism of action; Source EMA document) | Vascular Endothelial Growth Factor (VEGF) Receptor 2 is the key mediator of VEGF induced angiogenesis. Ramucirumab is a human receptor-targeted antibody that specifically binds VEGF Receptor 2 and blocks binding of VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits ligand stimulated activation of VEGF Receptor 2 and its downstream signalling components, including p44/p42 mitogen-activated protein kinases, neutralising ligand-induced proliferation and migration of human endothelial cells. |
| Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | |
| Original license holder | |
| Marketing authorisation numbers | EU/1/14/957/001 - 003 |
| Marketing authorisation holder | Eli Lilly Nederland B.V. Papendorpseweg 83 3528 BJ Utrecht The Netherlands |
| Name of the manufacturer of the biological active substance | ImClone Systems LLC 33 ImClone Drive, Branchburg New Jersey NJ 08876 UNITED STATES Eli Lilly S.A. Dunderrow Kinsale County Cork Ireland |
| Name and address of the manufacturer(s) responsible for batch release | Lilly, S.A. Avda de la Industria, 30 Alcobendas 28108 Madrid Spain |
| Max shelf life | 36 months |
| Storage conditions | 2°C – 8°C |
| List of excipients | Histidine Histidine monohydrochloride Sodium chloride Glycine (E640) Polysorbate 80 (E433) Water for injections |
Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.
Evidentic GmbH
Am Mühlenberg 10
14476 Potsdam | Germany
